Which works better, Wegovy or Zepbound?

Head-to-head efficacy claims depend on specific trials, populations, and endpoints, and effectiveness varies by individual. We do not rank medications. Discuss expected benefits and risks with a licensed clinician, and review each drug’s FDA labeling, linked on this page.

Can I switch between them?

Any change in medication is a clinical decision made with your prescriber. We do not provide personalized medical recommendations.

Is either one covered by insurance?

Coverage for weight-management drugs varies significantly by plan and often requires prior authorization. See our insurance guide for how to check your specific plan’s formulary.

Comparison

Wegovy vs. Zepbound: Side-by-Side Comparison

Wegovy and Zepbound are both FDA approved for chronic weight management and both are once-weekly injections — but they contain different active ingredients from different manufacturers, and Zepbound carries an additional FDA-approved indication for obstructive sleep apnea.

Editorially reviewed by the editorial teamLast updated August 12, 2026

Side-by-side comparison

Wegovy vs. Zepbound
	Wegovy	Zepbound
Active ingredient	Semaglutide	Tirzepatide
Drug class	GLP-1 receptor agonist	Dual GIP and GLP-1 receptor agonist
Manufacturer	Novo Nordisk	Eli Lilly and Company
FDA status (for weight management)	FDA ApprovedApproved for chronic weight management	FDA ApprovedApproved for chronic weight management
Approved indications	Chronic weight management in adults with obesity (BMI ≥30), or overweight (BMI ≥27) with at least one weight-related condition, as an adjunct to a reduced-calorie diet and increased physical activity Chronic weight management in pediatric patients aged 12 and older with obesity Reduction of risk of major adverse cardiovascular events (cardiovascular death, heart attack, stroke) in adults with established cardiovascular disease and either obesity or overweight	Chronic weight management in adults with obesity (BMI ≥30), or overweight (BMI ≥27) with at least one weight-related condition, as an adjunct to a reduced-calorie diet and increased physical activity Moderate-to-severe obstructive sleep apnea in adults with obesity
Administration	Subcutaneous injection (prefilled pen)	Subcutaneous injection (prefilled pen or single-dose vial)
Frequency	Once weekly	Once weekly
Approval date	June 2021 (adults); December 2022 (adolescents 12+); March 2024 (cardiovascular risk reduction)	November 2023 (weight management); December 2024 (obstructive sleep apnea)
Boxed warning	Yes — see drug page	Yes — see drug page
Common adverse reactions (from labeling)	Nausea, Diarrhea, Vomiting, Constipation, Abdominal pain, Headache, Fatigue, Dyspepsia (indigestion), Dizziness, Abdominal distension	Nausea, Diarrhea, Vomiting, Constipation, Abdominal pain, Dyspepsia (indigestion), Injection site reactions, Fatigue, Hypersensitivity reactions, Belching (eructation), Hair loss, GERD
Official information source	Prescribing information	Prescribing information

Every cell is drawn from the two medications’ FDA labeling as recorded on their individual pages: Wegovy and Zepbound. Where labeling does not establish a fact, the cell says so.

Key differences

Active ingredient: Wegovy is semaglutide (a GLP-1 receptor agonist); Zepbound is tirzepatide (a dual GIP and GLP-1 receptor agonist).
Manufacturer: Wegovy is made by Novo Nordisk; Zepbound by Eli Lilly.
Approved indications: both are approved for chronic weight management. Wegovy is additionally approved to reduce major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight; Zepbound is additionally approved for moderate-to-severe obstructive sleep apnea in adults with obesity.
Approval timing: Wegovy was approved for weight management in June 2021; Zepbound in November 2023.
Both require a prescription, and neither has an FDA-approved generic.

Important safety differences

Both labels carry the same boxed warning regarding thyroid C-cell tumors in rodents and contraindications in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.
The most common adverse reactions in both labels are gastrointestinal (nausea, diarrhea, vomiting, constipation, abdominal pain).
Because they act on different receptor combinations, individual tolerability can differ — this is a clinical judgment for a patient and their clinician, not something a website can predict.

Read both full labels

Summaries cannot substitute for the prescribing information. Both labels are linked in the table above and in Sources below.

Which one is right for you?

We can’t answer that, and neither can any website. Choosing between weight-management medications depends on your medical history, other conditions and medications, what your insurance covers, and how you tolerate a given drug — all of which require a licensed clinician who knows your case. What we can do is make sure the facts you bring to that conversation are accurate and traceable to their source.

Frequently asked questions

Which works better, Wegovy or Zepbound?: Head-to-head efficacy claims depend on specific trials, populations, and endpoints, and effectiveness varies by individual. We do not rank medications. Discuss expected benefits and risks with a licensed clinician, and review each drug’s FDA labeling, linked on this page.
Can I switch between them?: Any change in medication is a clinical decision made with your prescriber. We do not provide personalized medical recommendations.
Is either one covered by insurance?: Coverage for weight-management drugs varies significantly by plan and often requires prior authorization. See our insurance guide for how to check your specific plan’s formulary.

Sources

Wegovy prescribing information (DailyMed, NIH) — DailyMed/NIH. Link last verified August 12, 2026.
FDA: Medications containing semaglutide — FDA. Link last verified August 12, 2026.
Wegovy official site (Novo Nordisk) — Manufacturer. Link last verified August 12, 2026.
Zepbound prescribing information (DailyMed, NIH) — DailyMed/NIH. Link last verified August 12, 2026.
Drugs@FDA database — FDA. Link last verified August 12, 2026.
Zepbound official site (Eli Lilly) — Manufacturer. Link last verified August 12, 2026.

Not medical advice. WeightLossDrugsGuide is an independent educational publisher. We are not a pharmacy, a medical provider, or a telehealth clinic, and we do not provide personalized medical recommendations or dosing guidance. Information here summarizes official FDA labeling and other primary sources and may not reflect the most recent changes. Always talk with a licensed clinician about your own situation, and read the full prescribing information for any medication.